Biogen Inc. CEDEAR (BIIB)

Profile

https://www.biogen.com

Biogen Inc. is an American multinational biotechnology company specializing in treatments for neurological diseases and rare conditions. Based in Cambridge, Massachusetts, the company develops and commercializes a diverse portfolio of therapies including LEQEMBI and ADUHELM for Alzheimer's disease, TECFIDERA and AVONEX for multiple sclerosis, SPINRAZA for spinal muscular atrophy, and biosimilar medications. Biogen also produces several hemophilia treatments and collaborates with partners like Eisai and Genentech on drug development and commercialization. The company's research focuses on cutting-edge science in neurology, immunology, and rare diseases. With a market capitalization of approximately $27 billion and operations across multiple continents, Biogen remains a leading force in biopharmaceutical innovation, consistently advancing treatments for conditions previously considered difficult to address and transforming patient outcomes through scientific excellence.